Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.

Article Details

Citation

Copy to clipboard

Cha MY, Lee KO, Kang SJ, Jung YH, Song JY, Choi KJ, Byun JY, Lee HJ, Lee GS, Park SB, Kim MS

Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.

J Med Chem. 2012 Mar 22;55(6):2846-57. doi: 10.1021/jm201758g. Epub 2012 Mar 9.

PubMed ID

22372864 [ View in PubMed

]

Abstract

A novel series of N(4)-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine-4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance. The selected compound (19a) showed excellent inhibitory activity toward HER-1/HER-2 tyrosine kinases with selectivity over 20 other kinases and inhibited the proliferation of both cancer cell types: lapatinib-sensitive cell lines (SK-Br3, MDA-MB-175, and N87) and lapatinib-resistant cell lines (MDA-MB-453, H1781, and H1975). The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Lapatinib	Epidermal growth factor receptor	IC 50 (nM)	52.2	N/A	N/A	Details
Lapatinib	Receptor tyrosine-protein kinase erbB-2	IC 50 (nM)	36.3	N/A	N/A	Details